B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Graves’ Disease: A Controlled Pilot Study

Daniel El Fassi, Claus Henrik Nielsen, Steen Joop Bonnema, Hans Carl Hasselbalch, Laszlo Hegedüs

The Journal of Clinical Endocrinology & Metabolism · 2007 · 153 citations · 9 references

DOIFull text

Open access

Abstract

RTX treatment may induce sustained remission in patients with GD with low TRAb levels. However, RTX did not affect autoantibody levels and seems ineffective in patients with high TRAb levels. At present, high cost, low efficacy, and potential side effects do not support use in uncomplicated GD.

References

9